Just launched · October 2026—Rankings get sharper with every edition.Spotted an error?Tell us →
Sign in / Register

BlueNalu

ActiveOn the Alternative proteins Radar · not ranked

Alternative proteins · United States

Develops cultivated bluefin tuna toro grown from fish cells for sushi restaurants, working with Asian food partners and awaiting US FDA review.

HQUnited States
Last roundConvertible notes + preferred stock · Jan 2026

Why BlueNalu is not ranked yet

How the Radar works →

The Radar lists every known eligible company, sorted by date of last round, with no AI judgement. BlueNalu enters the ranking once its public data is sufficient for the AI to estimate it. Next Alternative proteins worldwide edition: 28 Feb 2027.

Funding history

DateRoundAmountTypeInvestors
Jan 2026Convertible notes + preferred stockUSD 11MEquityAgronomics, Siddhi Capital, Lewis & Clark AgriFood, Griffith Foods, Pulmuone, Rich Products

Mix of preferred shares and convertible notes; previous Series B of USD 33.5M (2023).

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
Alternative proteins · worldwideRadar—Edition 0 · Oct 202628 Feb 2027

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of BlueNalu as a PDF. It must answer at least one of these four questions, and stick to them:

ValuationWhat is BlueNalu worth?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Who should it acquireAcquisition targets, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Comparable companies in alternative proteins

Full alternative proteins ranking →

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.